An ongoing multicenter phase II randomized trial out of Canada is comparing upfront Osimertinib in addition to SRS to brain metastases to Osimertinib alone for patients with treatment-naive EGFR-mutated NSCLC with brain metastases [60]. Here, EGFR is linked to non-small cell lung carcinoma.